CMS Open Payments · Program Year 2024
Visionix USA, Inc
Visionix USA, Inc reported $108,907.94 across General Payments, Research, and Ownership to 85 physicians and teaching hospitals across 85 transactions.
- $108.9K Below-median payer
- All-tracks total
- 85 Below-median volume
- Transactions
- 85 Below-median reach
- Recipients
- #1161
- of 1,925 companies
Visionix USA, Inc reported $108,907.94 across all CMS Open Payments tracks (General + Research + Ownership) to 85 physicians and teaching hospitals in Program Year 2024 - ranking #1161 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $108,907.94, averaging $1.3K per recipient.
Visionix USA, Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
11/100
Total payments
F
11/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer visionix-usa-inc Visionix USA, Inc
$108.9K · #1161/1,925 · 0.0% industry · PY2024
- TOT $108.9K
- RANK #1161
- SHARE 0.0%
- TXN 85
- RCP 85
- CAT 1
- GEN $108.9K
- TOP1 17.4%
- PY 2024
Volume peers
Nearest volume peer: Sirona Dental Systems GmbH ($108.6K)
Visionix USA, Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Visionix USA, Inc
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Visionix USA, Inc that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
85 transactions worth $108.9K make "Food and Beverage" the top general-payment category in the 1-category breakdown below, 100.0% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Food and Beverage" leads Visionix USA, Inc's 1-category general-payment breakdown at $108.9K, 100.0% of the reported total.
How Visionix USA, Inc divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $108.9K | 85 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $73,407.96 (67.4%) of $108,907.94 in this company's General Payments records across 67 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Visionix USA, Inc
The five named recipients with the highest reported General Payments from this company
- 1
Julie RODMAN
$18,941.28 across 6 reported transactions
- 2
Nathan R Lighthizer
$18,000.00 across 4 reported transactions
- 3
Richard Rosen
$15,000.00 across 4 reported transactions
- 4
Jenna Lighthizer
$10,733.34 across 1 reported transactions
- 5
Aubry Tackett
$10,733.34 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Visionix USA, Inc's spend rank (#1161 of 1,925, bottom 40% by spend) and concentration rank (#972 of 1,838, bottom 47% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Optos, Inc. : $585.3K total payments, HHI 1153
- HemoSonics LLC : $100.7K total payments, HHI 1152
- Intercept Pharmaceuticals, Inc. : $2.8M total payments, HHI 1149
- Asensus Surgical, Inc. : $207.1K total payments, HHI 1147
- Alcresta Therapeutics, Inc. : $170.2K total payments, HHI 1141
- Pathway Medical Partners, LLC : $66.0K total payments, HHI 1140
- Visionix USA, Inc (this company) : $108.9K total payments, HHI 1138
- Anika Therapeutics, Inc. : $1.1M total payments, HHI 1135
- Woven Orthopedic Technologies, LLC : $1.2K total payments, HHI 1134
- MY01 Inc. : $29.5K total payments, HHI 1134
- Whitehall International Inc : $44.4K total payments, HHI 1133
- Prismatik Dentalcraft, Inc. : $485.7K total payments, HHI 1132
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Visionix USA, Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Visionix USA, Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Visionix USA, Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Nucletron Operations B.V.
Elevate Oral Care
60 Degrees Pharmaceuticals
Neoss, Inc.
Swing Therapeutics, Inc.
Put this to use
Visionix USA, Inc ranks #1161 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Visionix USA, Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.